The first MHLW-approved METex14 companion diagnostic
Archer®MET is the first MHLW-approved METex14 from new MHLW-approved targeted therapies.
ArcherMET tests for MET exon 14 (METex14) skipping mutations in non-small cell lung cancer (NSCLC) to identify patients who may benefit from new MHLW-approved targeted therapies.
METex14 skipping: An important biomarker for therapy selection
A new targeted therapy for NSCLC patients with METex14 alterations, highlighting why it’s important to know every patient’s status.
Prevalence of select NSCLC Oncogenic Alterations1-11
- METex14 skipping mutations lead to oncogenic MET signaling, resulting in poor prognosis.12
- Deregulation of the MET pathway via MET mutations plays an important role in acquired resistance to EGFR-TKIs.13
- METex14 skipping is associated with poor response to standard NSCLC therapies.14-18
There is now a new regulatory-approved targeted therapy for NSCLC patients with METex14 skipping
With ArcherMET, you can test for METex14 skipping mutations in NSCLC patients using tissue and blood samples
By including a step at the beginning of the test to check the quality of the RNA extracted from the sample, ArcherMET ensures that a high quality sample is available for analysis and increases the success rate of the test.
Expand your NSCLC testing workflow with ArcherMET
Reliable results you can trust
ArcherMET leverages proprietary Anchored Multiplex PCR (AMP™) technology that can efficiently and accurately detect METex14 skipping mutations by sequencing RNA from tissue and ctDNA from blood.
*Assays were performed on multiple known cohort samples and cancer samples. Analysis algorithm set to correctly call positive/negative, and results of calls made.
Minimal sample requirements that ensure patient access to testing
- Minimum 2 unstained FFPE slides
- 5-10 um thickness per slide
- Minimum 20mm2 tissue (the total area of the tissue should be determined from H&E)
- Nucleic acid content: >10 ng TNA
- 10 mL whole blood
- Nucleic acid content: >5 ng ctDNA
- No need for invasive tissue biopsy
Identify METex14-positive patients with ArcherMET so your NSCLC patients can receive effective therapy
How to order
ArcherMET is available for order through LSI Medience and SRL For instructions on to order and prepare samples, please contact each lab directly:
Learn more about ArcherMET by emailing us at the button below.
ArcherMET is only available for companion diagnostic use in Japan
Salgia R. Mol Cancer Ther. 2017;16:555-565.
Chakravarty D, Gao J, Phillips S, et al. JCO Precis Oncol. 2017. Accessed March 3, 2020.
Farago AF, Taylor MS, Doebele RC, et al. JCO Precis Oncol. 2018;2018.
AACR Project GENIE Consortium. Cancer Discov. 2017;7:818-831.
Ross JS, Ali SM, Fasan O, et al. Oncologist. 2017;22:1444-1450.
Gainor JF, Varghese AM, Ou SH, et al. Clin Cancer Res. 2013;19:4273-4281.
Mazières J, Peters S, Lepage B, et al. J Clin Oncol. 2013;31:1997-2004.
Lin Q, Zhang H, Ding H, et al. J Transl Med. 2019;17:1-10.
Tissot C, Couraud S, Tanguy R, et al. Lung Cancer. 2016;91:23-28.
Bergethon K, Shaw AT, Ou SH, et al. J Clin Oncol. 2012;30:863-870.
Awad MM, Oxnard GR, Jackman DM, et al. J Clin Oncol. 2016;34:721-730.
Awad MM, Leonardi GC, Kravets S, et al. Lung Cancer (suppl). 2019;133:96-102.
Ariyawutyakorn W, Saichaemchan S, Varella-Garcia M. J Cancer. 2016;7(6):633-49.
Dimou A, Leonardi GC, Kravets S, et al. PLoS One. 2014;9:e107677.
Guo B, Cen H, Tan X, et al. PLoS One. 2014;9:e99399.
Sabari JK, Leonardi GC, Shu CA, et al. Ann Oncol. 2018;29: 2085-2091.
Baba K, Tanaka H, Sakamoto H, et al. Thorac Cancer. 2019;10:369-372.
Reis H, Metzenmacher M, Goetz M, et al. Clin Lung Cancer. 2018;19:e441-e163.